8 results
Hodgkin's Lymphoma vs Non-Hodgkin's Lymphoma - Comparison

Hodgkin's Lymphoma:
 • Epidemiology: young adults 20-30, older 50-70
 •
Lymphoma - Comparison ... involvement Differential ... Malignancies (eg CML, ALL ... #NonHodgkins #comparison ... #hematology
Hodgkin's Lymphoma Overview

Hodgkin's lymphoma (HL) is an uncommon hematological malignancy arising from mature B cells. It
accounts for 10% of all ... Immunohistochemical studies (to differentiate ... number of sites of disease ... Lymphoma Treatment ... #oncology #management
Acquired von Willebrand Syndrome - Diagnosis and Management
 • Autoantibodies to vWF: Lymphoproliferative disorders (e.g. lymphoma,
Acquired von Willebrand ... Diagnosis and Management ... thrombocythemia), Autoimmune disease ... #treatment #hematology ... #differential
Polycythemia Vera (PV) - Diagnosis and Management Summary
Diagnostic Criteria:
 • Elevated hemoglobin and/or hematocrit AND
 •
Diagnosis and Management ... transformation into AML ... with evidence of acquired ... von Willebrand disease ... #hematology
Hemophagocytic Lymphohistiocytosis (HLH)
Pathophysiology: Triggering factor (infection,...)→Activation of CD8 T cells (IFN-y) → Excessive activation of macrophages
Purtilo (XLP) Acquired ... Hemopathies+++: Hodgkin ... Lymphohistiocytosis #diagnosis #management ... #treatment #summary ... #rheumatology
Drug Induced Lupus vs SLE
Drug Induced Lupus (DIL):
 • Epidemiology: -10% of all lupus cases, drug-dependent,
Usual therapeutic management ... Evolution: Chronic disease ... druginduced #lupus #sle #comparison ... #table #rheumatology ... #diagnosis #management
Myelodysplastic Syndromes (MDS)

What?
Myelodysplastic syndromes are a group of disorders caused by blood cells that are poorly
that are poorly formed ... Myeloproliferative Disease ... factor (GCSF) treatments ... blood count with differential ... Syndromes #diagnosis #hematology
Hemophagocytic Lymphohistiocytosis (HLH)

High mortality without prompt recognition and management. HLH is a critical diagnostic consideration in
recognition and management ... • In all patients ... • Secondary (Acquired ... ▪ Autoimmune diseases ... #Hematology #HemeOnc